About this item:

895 Views | 339 Downloads

Author Notes:

Correspondence: Chuan He, Department of Chemistry and Institute for Biophysical Dynamics, University of Chicago, Chicago, Illinois 60637; Email: chuanhe@uchicago.edu

or Jing Chen, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, Georgia 30322; Email: jchen@emory.edu

Authors' Contributions: The first two authors contributed equally to this work.

Acknowledgments: We thank Susan Sunay at the Hematology Division Tissue Bank, Winship Cancer Institute of Emory for providing primary tissue samples from leukemia patients, Drs. Sagar Lonial and Lawrence Boise for providing peripheral blood samples from healthy donors, and Dr. Yoke Wah Kow for human HaCaT and PIG1 cell lines.

Disclosures: J.X. and T.-L.G. are employees of Cell Signaling Technology, Inc.

T.H. is a Fellow Scholar of the American Society of Hematology.

S. E. is an NIH pre-doctoral fellow and an ARCS Foundation Scholar.

G.Z.C., D.M.S., F.R.K., S.K. and J.C. are Georgia Cancer Coalition Distinguished Cancer Scholars.

S. K. is a Robbins Scholar.

S.K. and J.C. are American Cancer Society Basic Research Scholars.

J.C. is a Scholar of the Leukemia and Lymphoma Society.

Subject:

Research Funding:

This work was supported in part by NIH grants CA120272 (J.C.), CA140515 (J.C.), GM071440 (C.H.) and the Pharmacological Sciences Training Grant T32 GM008602 (S.E.).

Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth

Show all authors Show less authors

Tools:

Journal Title:

Cancer Cell

Volume:

Volume 22, Number 5

Publisher:

, Pages 585-600

Type of Work:

Article | Post-print: After Peer Review

Abstract:

It remains unclear how cancer cells coordinate glycolysis and biosynthesis to support rapidly growing tumors. We found that glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), commonly upregulated in human cancers due to loss of TP53, contributes to biosynthesis regulation in part by controlling intracellular levels of its substrate 3-phosphoglycerate (3-PG) and product 2-phosphoglycerate (2-PG). 3-PG binds to and inhibits 6-phosphogluconate dehydrogenase in the oxidative pentose phosphate pathway (PPP), while 2-PG activates 3-phosphoglycerate dehydrogenase to provide feedback control of 3-PG levels. Inhibition of PGAM1 by shRNA or a small molecule inhibitor PGMI-004A results in increased 3-PG and decreased 2-PG levels in cancer cells, leading to significantly decreased glycolysis, PPP flux and biosynthesis, as well as attenuated cell proliferation and tumor growth.

Copyright information:

© 2012 Elsevier Inc. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Creative Commons License

Export to EndNote